The effect of testosterone replacement therapy on lower urinary tract symptoms (LUTS) in men

Introduction. Currently, there is a point of view that lower urinary tract symptoms (LUTS) and age-related testosterone deficiency (hypogonadism) in men should be considered as pathogenetically interrelated, age-associated chronic diseases characterized by a progressive course. These conditions can significantly reduce the quality and duration of life in men in the absence of adequate drug correction. Over the past decades, a new understanding of the key role of testosterone in maintaining the normal anatomical and functional state of the lower urinary tract in men has emerged. This has led to a revision of the place of testosterone drugs in the treatment of LUTS. The aim of the study is to study the clinical efficacy and prostatic safety of testosterone replacement therapy (TRT) in men with testosterone deficiency (hypogonadism) and LUTS. Material and methods. The results of the examination and treatment of 45 men aged 40-70 years (mean age 56,3±3,2 years) with testosterone deficiency (hypogonadism) and LUTS (main group) and the results of the examination of 30 healthy men of the same age (control group) are presented. All men were surveyed using the IPSS-QL and AMS questionnaires; laboratory determination of blood levels of total PSA, total testosterone, sex hormone-binding globulin (SHBG), calculation of free testosterone levels using the Vermeulen nomogram; uroflowmetry with determination of the voided volume (VV) and the maximal flow rate (Qmax); ultrasound examination with determination of the prostate volume and residual urine, followed by statistical processing of the results according to standard methods.